venture capital,money,business,Investor

The company plans to start clinical development next year. Its focus is on bispecific antibodies – a form of cancer immunotherapy – that use gamma-delta “surveillance” T cells.

LEAVE A REPLY

Please enter your comment!
Please enter your name here